The 79th Annual Meeting of the Japanese Cancer Association

Day 3 October 3 (Saturday)

87

AMPM

LSAM

PMLS

AMPM

LSD

AY 1

INFO

RMA

TION

DA

Y 2DAY 3

Oral

ML

ICIN

DEX

AuthorsKeyw

ordsChairpersons

PosterSSP

1-2 Core Symposia

Room 1 Oct. 3 (Sat.) 9:00-11:30 E

CS3 Clinical trial translation to the daily clinic 臨床試験から実践医療へ

Chairpersons: Stanley Hamilton (Dept. Path. at City of Hope) Katsuya Tsuchihara (Div. Translational Informatics, Exploratory Oncology Res. & Clin. Trial Ctr., Natl. Cancer Ctr.)

座長：Stanley Hamilton (Dept. Path. at City of Hope) 土原 一哉（国立がん研セ・先端医療開発セ・トランスレーショナルインフォマティクス分野）

In the past decade, the framework of research and development of cancer therapies has been drastically changing. Molecular biology-based, tumor agnostic concept is overwriting existing anatomical and histological subclassification of solid tumors. The integrated patient registry system is necessary to propel clinical trials. And a rush of newly developed drugs and biomarker testing demands clinicians to choose highly complicated decision ladders. In the meantime, biologists are challenged to clarify the underlying molecular mechanisms of newly developed drug-host interactions. We like to discuss the achievement and perspective and seek a new way to cultivate the wilderness of precision oncology.

CS3-1 Precision Oncology 2020: Results and Lessons from the NCI-MATCH Clinical Trial Stanley R. Hamilton (Dept. Path., COHNMC)

CS3-2 Activity on Nationwide Cancer Genome Screening Project for Advanced Solid Tumors; SCRUM-Japan GI-/MONSTAR-SCREEN Takayuki Yoshino (Dept. Gastrointestinal Oncology, Natl. Cancer Ctr. Hosp. East) 全国がんゲノムスクリーニングプロジェクトSCRUM-Japan GI-/MONSTAR-SCREENの概要と成果 吉野 孝之（国立がん研セ・東病院消化管内科）

CS3-3 Cohorts and biobanks as essential resources for accelerating precision medicine in cancer Yoshinori Murakami1, Koichi Matsuda2, Takayuki Morisaki1, Yukihide Momozawa3, Toshiki Watanabe4, Yataro Daigo5, Kenji Wakai6 (1Div. Mol. Pathol., Inst. Med. Sci., The Univ. Tokyo, 2Lab. Clin. Seq, Grad. Schl. Front. Sci., The Univ. Tokyo, 3Lab. Genotyping Develop., RIKEN Ctr. Integrat. Med. Sci., 4Dept. Pract. Manage., St. Marianna Univ. Grad. Schl. Med., 5Ctr. Antibody Vaccine Therapy, Inst. Med. Sci., The Univ. Tokyo, 6Dept. Prevent. Med., Nagoya Univ. Grad. Schl Med.) がんの精密医療の加速に必須な基盤としてのコホート・バイオバンク 村上 善則1、松田 浩一2、森崎 隆幸1、桃沢 幸秀3、渡邉 俊樹4、醍醐 弥太郎5、若井 建志6（1東京大・医科研・人癌病因遺伝子、2東京大・新領域・シークエンシング、3理研・生命医セ・基盤技術開発、4聖マリ医大・院医療情報、5東京大・医科研・抗体ワクチンセ、6名古屋大・院医・予防医学）

CS3-4 Importance of pathology for precision oncology Satoshi Fujii1,2 (1Dept. Mol. Pathol., Yokohama City Univ. Sch. of Med., 2Natl. Cancer Ctr. Hosp. East, Pathol. & Clin. Lab.) Precision oncology 実現のための病理学の重要性 藤井 誠志1,2（1横浜市大・院医・分子病理学、2国立がん研セ・東病院病理臨床検査科）

CS3-5 TBD Thomas Brown (Syapse, Inc.)

Symposia

Room 2 Oct. 3 (Sat.) 9:00-11:30 E

S15 Cancer Immunotherapy based on diversity of tumor-immune interaction 腫瘍免疫病態の多様性とがん治療

Chairpersons: Koji Tamada (Dept. Immunol., Yamaguchi Univ. Grad. Sch. of Med.) Kazuma Kiyotani (Cancer Precision Med. Ctr., Immunopharmacogenomics Group, Japanese Foundation for Cancer Res.)

座長：玉田 耕治（山口大・院医・免疫学講座） 清谷 一馬（（公財）がん研・がんプレシジョン医療研究セ・免疫ゲノム解析グ）

Cancer immunotherapy is one of the major treatment options for cancer after development of immune checkpoint inhibitors targeting CTLA4, PD-1 and PD-L1 molecules. However, only a subset of patients has clinical benefit of immune checkpoint inhibitors. Since T cells as well as other immune cells play main roles in the anti-tumor immune responses, several approaches have been investigated to develop novel immunotherapy by increasing the numbers of T cells and enhancing their anti-tumor functions in the tumor site. In this symposium, we will discuss a variety of potential strategies of immunotherapy, including an artifical adjuvant vetor to enhance NKT cells and cancer-specific T cells, cancer peptide vaccine therapy targeting cancer-specific T cells, and more efficient gene engineered anti-tumor T cells such as chimeric antigen-receptor (CAR)-T cells and T cell receptor (TCR)-T cells targeting neoantigens. The findings from these researches will lead to development of more effective immunotherapy for cancer.

S15-1 Anti-cancer therapeutic cellular drug, artificial adjuvant vector cells by targeting in vivo dendritic cells Shin-ichiro Fujii (Lab. Immunotherapy, RIKEN, IMS) 樹状細胞を標的とした抗腫瘍細胞治療“人工アジュバントベクター細胞” 藤井 眞一郎（理研・IMS免疫細胞治療研究チーム）

S15-2 Phase II adjuvant peptide vaccine for postoperative esophageal cancer patients with pathologically positive nodes Takushi Yasuda1, Kohei Nishiki2, Yoko Hiraki1, Hiroaki Kato1, Osamu Shiraishi1, Atsushi Yasuda1, Masayuki Shinkai1, Yutaka Kimura1, Yasushi Sukegawa3, Yasutaka Chiba4, Motohiro Imano1, Kazuyoshi Takeda5, Takao Satou6, Hitoshi Shiozaki1, Yusuke Nakamura7 (1Dept. Surg., Kindai Univ., Fac. Med., 2Dept. Surg., Ohita Nakamura Hosp., 3Life Sci. Res. Inst., Kindai Univ., 4Clin. Res. Ctr., Kindai Univ. Hosp., 5Div. Cell Biol., Biomed. Res. Ctr., Juntendo Univ. Sch. Med., 6Div. Hosp. Pathol., Kindai Univ. Hosp., 7Cancer Precision Med. Ctr.) 術前治療後治癒切除のpN(+)食道癌症例に対するペプチドワクチン術後補助療法に関する探索的単施設第2相臨床試験 安田 卓司1、錦 耕平2、平木 洋子1、加藤 寛章1、白石 治1、安田 篤1、新海 政幸1、木村 豊1、助川 寧3、千葉 康敬4、今野 元博1、竹田 和由5、佐藤 隆夫6、塩崎 均1、中村 祐輔7（1近畿大・医・外科、2大分中村病院・外科、3近畿大・ライフサイエンス研、4近畿大・病院・臨床研究セ、5順天堂大・医・研究基盤セ、6近畿大・病院・病院病理部、7（公財）がん研・がんプレシジョン医療研究セ）

S15-3 Cancer-reactive/neoantigen-specific T cells in peripheral blood, tumor and lymph node tissues of cancer patients Kazuma Kiyotani, Yusuke Nakamura (Cancer Precision Med. Ctr., JFCR) がん組織及びリンパ節中のがん反応性/ネオアンチゲン特異的 T 細胞 清谷 一馬、中村 祐輔（（公財）がん研・がんプレシジョン医療研究セ）

S15-4 Combined targeting of tumor-stroma and cancer cells by T cells is essential for eradication of solid tumors Steven P. Wolf1,2,4, Vasiliki Anastasopoulou4, Madeline Steiner1, Markus I. Diehl1, Kimberley Borutta4, Boris Engels1, Poh Yin Yew3, Kazuma Kiyotani5, Yusuke Nakamura5, Karin Schreiber1,2, Hans Schreiber1,2, Matthias Leisegang4 (1Dept. of Pathology, University of Chicago, Chicago, USA, 2David and Etta Jones Center Cellular Therapy, University of Chicago, 3Department of Medicine, University of Chicago, Chicago, USA, 4Institute of Immunology, Charite, Campus Buch, Berlin, Germany, 5Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Japan)

S15-5 Next generation CAR-T cell therapy for solid tumors Koji Tamada (Yamaguchi Univ., Sch. Med.) 固形がんに対する次世代CAR-T 細胞療法の研究と開発 玉田 耕治（山口大・医・免疫学）

88

0-1

Symposia

Room 3 Oct. 3 (Sat.) 9:00-11:30 E

S16 Evolvement of targeted drug therapy 分子標的治療薬の新展開

Chairpersons: Seiji Yano (Div. Med. Oncology, Kanazawa Univ. Cancer Res. Inst.) Takumi Kawabe (CanBas Co., Ltd.)

座長：矢野 聖二（金沢大・がん研・腫瘍内科学） 河邊 拓己（株式会社キャンバス）

In the 21st century, molecularly targeted therapies for cancer have made great strides. More than 40 drugs have been approved for various cancer types, and dramatic improvement in prognosis has been achieved for patients by targeting driver oncogene drug targets. On the other hand, many issues have remained. For instance, there are many cases of relapse due to resistance or tolerance to molecularly targeted drugs. In addition, there are still many cancer types for which no targeted drugs are available. In recent years, development of drugs for new targets and for resistant tumors has progressed based on some new ideas. In this session, 6 experts will give cut-ting-edge lectures on antibody-drug conjugates, micellized targeted drugs, nucleic acid drugs, drugs for resistant/tolerant tumors, drugs for central nervous system metastasis, and molecularly targeted drugs for KRAS mutant tumors. We look forward to many people participating and providing fruitful discussions.

S16-1 Development of novel antibody-drug conjugates Shunji Takahashi (Dept, Med. Oncology, Cancer Instutute Hosp., JFCR) Antibody-Drug Conjugate の新展開 高橋 俊二（（公財）がん研・有明病院・総合腫瘍科）

S16-2 Latest Advancement of Targeted Drug Therapy using Polymer Micelle Sabina Quader1, Kazunori Kataoka1,2, Horacio Cabral3, Hiraoki Kinoh1, Xueying Liu1, Hitoshi Shibasaki1,4, West Paraiso1 (1Innovation Ctr. of NanoMed. (iCONM), Kawasaki Inst. of Industrial Promotion, 2Inst. for Future Initiatives, The Univ. of Tokyo, 3Dept. Bioengineering, The Univ. of Tokyo, 4Dept. Otolaryngology, The Univ. of Tokyo)

S16-3 The potential for microRNA therapeutics: Pre-clinical study of locally administered miRNA for malignant mesothelioma Hidetoshi Tahara (Dept. Cell. Mol. Biol, Grad. Sch. Biomed. Health Sci., Hiroshima Univ.) 悪性胸膜中皮腫を対象とした局所投与型マイクロRNA核酸医薬の非臨床試験 田原 栄俊（広島大・院・細胞分子生物）

S16-4 Novel mechanisms of tolerance and resistance to targeted drugs Franziska Haderk1,2, Celia Fernandez-Mendez3, Wei Wu1,2, Khyati Shah2,4, Juan Guan5, Julia Rotow1,2, David Allegakoen1,2, Daniel Lucas Kerr1,2, Dora Barbosa1,2, Victor Olivas1,2, Sourav Bandyopadhyay2,4, Calvin Kuo6, Trever G Bivona1,2 (1Dept. Med., UCSF, 2Helen Diller Family Comprehensive Cancer Ctr., UCSF, 3Inst. for Biomed. Res. Alberto Sols, Madrid, 4Dept. Bioengineering & Therapeutic Sceinces, UCSF, 5Dept. Pharm. Chemistry, UCSF, 6Dept. Med., Stanford)

S16-5 Mechanisms of Targeted Drug Resistance in Central Nervous System (CNS) Akihiro Nishiyama, Sachiko Arai, Koji Fukuda, Shigeki Sato, Naohiro Yanagimura, Chiaki Suzuki, Azusa Tanimoto, Kaname Yamashita, Shinji Takeuchi, Koushiro Ohtsubo, Seiji Yano (Div. Med. Oncology Cancer Res. Inst., Kanazawa Univ.) 中枢神経系転移における耐性機構 西山 明宏、新井 祥子、福田 康二、佐藤 成樹、柳村 尚寛、鈴木 千晶、谷本 梓、山下 要、竹内 伸司、大坪 公士郎、矢野 聖二（金沢大・がん研・腫瘍内科）

S16-6 Selective Targeting to KRAS-driven Lung Tumorigenesis via Unresolved ER stress Iwao Shimomura1,2, Minami Kumazaki1, Yuji Tada2,3, Koichiro Tatsumi2, Takahiro Ochiya4, Yusuke Yamamoto1 (1Div. Cell. Sig., Natl. Cancer Ctr. Res. Inst., 2Dept. Resp., Grad. Sch. Med., Chiba Univ., 3Dept. Resp., Sch. Med., Int. Univ. Health & Welfare., 4Dept. Mol. Cell. Med., Inst. Med. Sci., Tokyo Med. Univ.) KRAS 変異肺がんにおける小胞体ストレス誘導を介した新規治療開発 下村 巌1,2、熊崎 実南1、多田 裕司2,3、巽 浩一郎2、落谷 孝広4、山本 雄介1（1国立がん研セ・研・細胞情報学、2千葉大・院医・呼吸器内科学、3国際医療福祉大・医・呼吸器内科、4東京医大・医総研・分子細胞治療）

JCA - Mauvernay Awards Session

Room 4 Oct. 3 (Sat.) 9:00-11:30 E

MVA JCA - Mauvernay Awards Session JCA-モヴェルネアワードセッション

Chairpersons: Masanori Hatakeyama (Dept. Microbiology, Grad. Sch. of Med., The Univ. of Tokyo) Johji Inazawa (Med. Res. Inst., Tokyo Med. & Dent. Univ.)

座長：畠山 昌則（東京大・院医・微生物学） 稲澤 譲治（東京医歯大・難治研・分子細胞遺伝分野）

MVA-1 Recent translational approach for pancreatic cancer Shin Maeda (Dept. Gastroenterology, Yokohama City Univ.) 膵臓癌に対するトランスレーショナルアプローチ 前田 愼（横浜市大・医・消化器内科学）

MVA-2 The molecular pathogenesis of leukemia and myelodysplastic syndromes Mineo Kurokawa (Dept. Hematol. Oncol., Grad. Sch. Med., Univ. Tokyo) 白血病と骨髄異形成症候群の発症機構 黒川 峰夫（東京大・医・血液・腫瘍内科）

MVA-3 Mieap liquid droplets: a new concept in mitochondrial quality control and tumor suppression Hirofumi Arakawa (Div. Cancer Biol., Natl. Cancer Ctr. Res. Inst.) Mieap 液滴：ミトコンドリア品質保証とがん抑制に関する新しい概念 荒川 博文（国立がん研セ・研・腫瘍生物）

MVA-4 How genetic alterations promote malignant progression of colon cancer Masanobu Oshima1,2, Mizuho Nakayama1,2, Hiroko Oshima1,2 (1Div. Genet., Cancer Res. Inst., Kanazawa Univ., 2WPI Nano-Life Sci. Inst. Kanazawa Univ.) ドライバー変異が誘導する個体レベルでの大腸がん段階的悪性化プロセス 大島 正伸1,2、中山 瑞穂1,2、大島 浩子1,2（1金沢大・がん研・腫瘍遺伝、2金沢大・ナノ研）

MVA-5 Development of Synthetic Lethal Therapy for Chromatin Regulator Deficient Cancers Hideaki Ogiwara (Div. Cancer Therap., Nat Can Cen Res. Inst.) クロマチン制御因子欠損がんを対象とした合成致死治療法の開発 荻原 秀明（国立がん研セ・研・がん治療学研究分野）

MVA-6 Genetic dissection of molecular pathogenesis in human cancer Keisuke Kataoka (Div. Molecul. Oncol., Natl. Cancer Ctr. Res. Inst.) がん分子病態の遺伝学的解明 片岡 圭亮（国立がん研セ・研・分子腫瘍）

89

Room

1-4 2-3

AMPM

LSAM

PMLS

AMPM

LSD

AY 1

INFO

RMA

TION

DA

Y 2DAY 3

Oral

ML

ICIN

DEX

AuthorsKeyw

ordsChairpersons

PosterSSP

5-6 International Sessions

Room 5 Oct. 3 (Sat.) 9:00-11:30 E

IS9 New therapeutic strategy for controlling metastasis and relapse in cancer がん転移と再発に対する新規治療戦略

Chairpersons: Kohei Miyazono (Dept. Mol. Path., Grad. Sch. of Med., The Univ. of Tokyo) Seong Jin Kim (Precision Med. Res. Ctr., Advanced Inst. of Convergence Tech., Seoul Natl. Univ.)

座長：宮園 浩平（東京大・院医・分子病理学） Seong Jin Kim (Precision Med. Res. Ctr., Advanced Inst. of Convergence Tech., Seoul Natl. Univ.)

During the course of cancer, relapse occurs through survival of a few original cancer cells after initial treatment. Dissemination and metastasis of cancer can be seen even in the early stages of cancer, but after relapse of cancer, cancer cells often acquire resistance to conventional treatment and exhibit high metastatic abilities. Metastasis and relapse of cancer are thus closely related to the poor prognosis of various cancers. Recently, various approaches have been undertaken to combat relapse and metastasis of cancer. Epithelial-mesenchymal transition (EMT) in cancer cells and stromal fibroblasts has been shown to induce invasion, metastasis, and resistance to chemotherapy, and thus regulation of EMT phenotype may be a potentially interesting therapeutic strategy for advanced-stage cancer. Functions of cancer cells are influenced by the extracellular matrix (ECM) and tumor microenvironment, and regulation of angiogenesis has been shown to control cancer progression. In addition, inflammation and evasion of immune surveillance induce the progression of cancer metastasis. This International Session will discuss the complex roles of cancer cells and tumor microenvironment in progression of metastasis and relapse of cancer. Novel strategies for treatment of metastasis will also be discussed.

IS9-1 RNF208, a novel estrogen-inducible E3 ligase, targets soluble Vimentin to suppress metastasis Seong Jin Kim1, Kyoungwha Pang1, Toshikazu Ushijima2, Akira Ooshima1, Kyung-Min Yang1 (1Precision Med. Res. Ctr., AICT, Seoul Natl. Univ., Korea, 2Div. Epigenomics, Natl. Cancer Ctr. Res. Inst., Tokyo, Japan)

IS9-2 Novel approach for treatment of oral squamous cell carcinoma Katarzyna A. Inoue1, Shintaro Sakakitani2, Kazuki Takahashi1, Hiroyuki Harada2, Tetsuro Watabe1 (1Dept. Biochem., Grad. Sch., Tokyo Med. & Dent. Univ., 2Dept. Oral Maxillofacial Surg., Grad. Sch., Tokyo Med. & Dent. Univ.) 口腔扁平上皮がんに対する新たな治療を目指して 井上 カタジナアンナ1、榊谷 振太郎2、高橋 和樹1、原田 浩之2、渡部 徹郎1（1東京医歯大・院・硬生化学、2東京医歯大・院・顎口腔外科学）

IS9-3 VEGF-A and anti-PD-1 blocking therapy Eui-Cheol Shin (Grad. Sch. of Med. Sci. & Engineering, KAIST)

IS9-4 BMP signaling as a potential therapeutic strategy for DIPG Qiaoran Xi (Sch. of Life Sci., Tsinghua Univ.)

IS9-5 Mechanisms of neutrophi-dependent metastasis of inflammatory renal cell carcinoma Kohei Miyazono, Shogo Ehata, Jun Nishida, Kei Takahashi (Dept. Mol. Pathol., Grad. Sch. Med., Univ. Tokyo) 炎症性腎細胞がんの好中球依存性転移の分子機構 宮園 浩平、江幡 正悟、西田 純、高橋 恵生（東京大・医・分子病理）

IS9-6 The lysophospholipid metabolism enzyme Gdpd3 maintains chronic myelogenous leukemia stem cells Kazuhito Naka1, Seong-Jin Kim2 (1Dept. Stem Cell Biol., Res. Ins. RadiationBiol. Med., Hiroshima Univ., 2AICT, Seoul Natl. Univ.) リゾリン脂質代謝酵素Gdpd3によるCML幹細胞の維持機構 仲 一仁1、Seong-Jin Kim2（1広島大・原医研・幹細胞機能学、2AICT, Seoul Natl. Univ.）

IS9-7 Brg1, a subunit of the SWI/SNF complex, is critical for growth and metastasis of pancreatic cancer cells in mice. Osamu Araki, Akihisa Fukuda, Motoyuki Tsuda, Mayuki Omatsu, Mio Namikawa, Makoto Sono, Yuichi Fukunaga, Tomonori Masuda, Munemasa Nagao, Takaaki Yoshikawa, Satoshi Ogawa, Yukiko Hiramatsu, Takahisa Maruno, Yuki Nakanishi, Hiroshi Seno (Dept. Gastroenterology & Hepatology, Kyoto Univ.) SWI/SNF 複合体のサブユニットであるBrg1 はマウス膵癌の増殖・転移に重要である 荒木 理、福田 晃久、津田 喬之、尾松 万悠紀、並川 実桜、薗 誠、福永 裕一、益田 朋典、長尾 宗政、吉川 貴章、小川 智、平松 由紀子、丸野 貴久、中西 祐貴、妹尾 浩（京都大・院医・消化器内科学）

Cancer Science Young Scientists Award Lectures

Room 6 Oct. 3 (Sat.) 9:00-11:30 E

YSA Cancer Science Young Scientists Award Lectures Cancer Scienceヤングサイエンティストアワード受賞講演

Chairperson: Masahide Takahashi (Internatl. Ctr. for Cell & Gene Therapy, Fujita Health Univ.)

座長：高橋 雅英（藤田医大・国際再生医療セ）

YSA-1 Drug repositioning for sensitizing cancer cells to GSH-depleting therapy Otsuki Yuji, Osamu Nagano, Hideyuki Saya (Gene Regulation, IAMR, Keio Univ. Sch. Med.) ドラッグリポジショニングを介したグルタチオン欠乏療法に対する増感剤の開発 大槻 雄士、永野 修、佐谷 秀行（慶應大・医・先端医研 遺伝子制御）

YSA-2 SDPR Regulates ALDH1 via ILK Signaling in Endometrioid Carcinoma Cells Shinichiro Tahara1, Satoshi Nojima1, Kenji Ohshima1, Yumiko Hori1, Masako Kurashige1, Naoki Wada1, Yuichi Motoyama1, Daisuke Okuzaki2, Jun-ichiro Ikeda1, Eiichi Morii1 (1Dept. Pathol., Osaka Univ., Sch. Med., 2Genome Information Res. Ctr., RIMD, Osaka Univ.) SDPR は子宮体部類内膜癌において ILK を介してALDH1を制御する 田原 紳一郎1、野島 聡1、大島 健司1、堀 由美子1、倉重 真沙子1、和田 直樹1、本山 雄一1、奥崎 大介2、池田 純一郎1、森井 英一1（1大阪大・院医・病態病理、2大阪大・微研・遺伝情報実験セ）

YSA-3 Extracellular ATP promotes breast cancer invasion and EMT via HIF-2a signaling Hui Yang1,2, Yue-Hang Geng1, Peng Wang3, Wei-Gang Fang1, Xin-Xia Tian1 (1Dept. Path., PKU, 2Translational Cancer Res. Ctr., PKU 1st Hosp., 3Office of Scientific Res. PKUHSC)

YSA-4 LUCAT1 promotes CRC tumorigenesis by targeting the RPL40- MDM2- P53 pathway through binding with UBA52 Qianwen Zhou (Nanjing Med. Univ.)

90

4-5

International Sessions

Room 7 Oct. 3 (Sat.) 9:00-11:30 E

IS10 What kinds of data could help support UHC for cancer care in Asia in a COVID-19 world?

Chairpersons: HRH Princess Dina Mired (President for Union for Internatl. Cancer Control) Wataru Yasui (Dept. Mol. Pathol., Hiroshima Univ.) Kazuhiro Yoshida (Dept. Surg. Oncol. Gifu Univ.)

座長：HRH Princess Dina Mired (President for Union for Internatl. Cancer Control) 安井 弥（広島大・院医・分子病理） 吉田 和弘（岐阜大・医・腫瘍外科）

The cancer care frontline in Asia in danger of collapse due to the expanding COVID-19 crisis. Now is the time to take a long-term perspective and aim to create self-sustaining mechanisms that are independent from ODA funds that will ensure UHC for cancer care into the future. The current pandemic has brought with it a need to find a new normal for cancer care. So how can we realize UHC and ensure no-one is left behind? What is the best way to provide care? UICC-ARO has been a consistent supporter of cancer registries. Data is critical for supporting UHC policies, but what kinds of data can best support the provision of UHC? In what scenarios can data play a role in UHC policies? Could information infrastructure be created that shares information on the patient journey from diagnosis through to treatment and post-treatment progress among all stakeholders? Could registries be created with reference functions suitable for use in telemedicine? Utilizing the ACTION Study framework, which could provide a solid base for UHC research in Asia, in this session we will look at the potential for public-private cooperation on initiatives to resolve the challenges surrounding UHC in Asia. IS10-1 Opening Remarks

UICC and Universal Health Coverage HRH Princess Dina Mired (President for Union for Internatl. Cancer Control)

IS10-2 Provision as an effective means to ensuring a future for UHC Saunthari Somasundaram (Natl. Cancer Society Malaysia)

IS10-3 Current status of Asian cancer registries and future challenges Tomohiro Matsuda (Natl. Cancer Ctr., Ctr. for Cancer Controll & Information Services) アジアのがん登録の現状 松田 智大（国立がん研セ・がん対策情報センター・がん登録セ）

IS10-4 Challenges facing UHC for cancer care in Asia from the perspective of the ACTION Study Nirmala Bhoo Pathy (Dept. Social & Preventive Med., Faculty of Med., Univ. of Malaya)

IS10-5 Creating patient value and information infrastructure Toshio Takiguchi (CANON MEDICAL SYSTEMS) 瀧口 登志夫（キャノンメディカルシステムズ（株））

IS10-6 Possible commitment of Japanese pathologists in Asian oncology network for UHC Haruhiko Sugimura (Hamamatsu Univ. Sch. of Med., Dept. Tumor Path.) ユニバーサルヘルスカバレッジを目指すアジアのがん医療ネットワークに日本の病理医が関与する可能性 椙村 春彦（浜松医大・腫瘍病理学講座）

Symposia

Room 8 Oct. 3 (Sat.) 9:00-11:30 E

S17 Aging and Cancer 老化とがん

Chairpersons: Eiji Hara (Dept. Mol. Microbiology, Osaka Univ., Res. Inst. for Microbial Diseases) Hiroyuki Seimiya (Div. Mol. Biotherapy, Cancer Chemother. Ctr., Japanese Foundation for Cancer Res.)

座長：原 英二（大阪大・微研・遺伝子生物学） 清宮 啓之（（公財）がん研・化療セ・分子生物治療研究部）

Aging is the largest risk factor for the development of cancer, yet very little is known about how aging promotes cancer development. Given the important role of aging in human cancer development, it is clear that more focus should be placed on discovering and deciphering the key molecular pathways involved in aging-associated cancer. In particular, recent advances in genomic and epigenomic studies and stem cell biology made it possible to perform comparative genomic/epigenomic profiling of various tissue stem cells throughout aging. This approach, together with human organoid technology, will unveil the molecular pathways integrating the genomic/epigenomic alteration of stem cell function and oncogenic transfor-mation during the aging process. In this symposium, four invited speakers will present novel findings in the cutting-edge field of aging-associated cancer. Also, time will be allotted for two short oral presentations selected from submitted abstracts. We hope that this symposium will allow you to evaluate the latest evidence that links components of the aging process to cancer and to clarify, where possible, how these components accelerate car-cinogenesis.

S17-1 Roles and mechanisms of cellular senescence in the regulation of carcinogenesis Eiji Hara1,2 (1Res. Inst. for Microbial Diseases, Osaka Univ., 2IFReC, Osaka Univ.) 発がん制御における細胞老化の役割とそのメカニズム 原 英二1,2（1大阪大・微研・遺伝子生物、2大阪大・免疫フロンティア研究セ・老化生物）

S17-2 Telomere shortening and hTERT activation contribute stem cells and carcinogenesis of the pancreas Yoko Matsuda1, Toshiyuki Ishiwata2, Kenkichi Masutomi3, Juanjuan Ye1, Yuko Narusawa1, Keiko Yamakawa1, Masanao Yokohira1, Kaiyo Takubo2, Tomio Arai2 (1Oncology Path., Dept. Pathol. Host-Defense, Fac. Med., Kagawa Univ., 2Dept. Pathol., Tokyo Metro. Geriatric Hosp., 3Div. Cancer Stem Cell, Natl. Cancer Ctr. Res. Inst.) 膵臓の幹細胞と発癌におけるテロメア長の短縮とhTERT 活性化の役割の検討 松田 陽子1、石渡 俊行2、増富 健吉3、葉 娟娟1、成澤 祐子1、山川 けいこ1、横平 政直1、田久保 海誉2、新井 冨生2（1香川大・医・腫瘍病理学、2東京都健康長寿医療セ・病理、3国立がん研セ・がん幹細胞研究分野）

S17-3 Phenotypic trade-off between hair graying and melanoma Emi Nishimura (Tokyo Medical and Dental University, Medical Research Institute) 加齢による白髪とメラノーマ 西村 栄美（東京医科歯科大学・難治疾患研究所）

S17-4 Microenvironmental regulation of somatic evolution and tumorigenesis Masayuki Fujii, Toshiro Sato (Dept. Organoid Med., Keio Univ., Sch. Med.) 組織環境と体細胞性変異・がん化の相互連関 藤井 正幸、佐藤 俊朗（慶應大・医・オルガノイド医学）

S17-5 Age-related mutations in esophageal epithelium Seishi Ogawa (Dept. Path. & Tumor Biol., Kyoto Unv.) 加齢にともなった食道上皮の体細胞変異 小川 誠司（京都大・医・腫瘍生物）

S17-6 Age-dependent phenotypic conversion from neuronal activity to neuro-inflammation in glioblastoma progression Daisuke Yamashita1,2, Ichiro Nakano2 (1Dept. Neurosurg., Ehime Univ. Grad. Sch. of Med., 2Dept. Neurosurg., Univ. of Alabama at Birmingham) 膠芽腫の進展における加齢に伴う形質転換　－新たな亜型分類とともに－ 山下 大介1,2、中野 伊知郎2（1愛媛大・医・脳神経外科、2アラバマ大・バーミングハム校 脳神経外科）

91

Room

5-8 6-7

AMPM

LSAM

PMLS

AMPM

LSD

AY 1

INFO

RMA

TION

DA

Y 2DAY 3

Oral

ML

ICIN

DEX

AuthorsKeyw

ordsChairpersons

PosterSSP

Symposia on Specific Tumors

Room 9 Oct. 3 (Sat.) 9:00-11:30 J

SST5 Advances in Basic and Clinical Research on Hepatocellular Carcinoma 肝がん治療の基礎と臨床の進歩

Chairpersons: Kazuaki Chayama (Dept. Gastroenterology & Metabolism, Grad. Sch. of Biomed. & Health Sci., Hiroshima Univ.) Hideki Ohdan (Dept. Gastroenterological & Transplant Surg., Grad. Sch. of Biomed. & Health Sci., Hiroshima Univ.)

座長：茶山 一彰（広島大・院医・消化器・代謝内科学） 大段 秀樹（広島大・院医・消化器・移植外科学）

Recent advances in diagnostic imaging and treatment techniques have markedly improved the prognosis of patients with hepatocellular carcinoma (HCC). Safety and local curability of hepatic resection for patients with early stage HCC have dramatically improved. On the other hand, there is no established strategy to prevent metastatic recurrence of HCC after surgery. For advanced-stage HCC, multi-molecular target agents have become available in recent years, and last year combination therapy with an immune checkpoint inhibitor and an angiogenic factor inhibitor was shown to be effective. Systemic therapy for HCC is thus about to enter a new era. However, no valid biomarkers for therapeutic efficacy, safety, and drug selection have yet been established. To further improve patient prognosis, it will be necessary to clarify the underlying carcinogenic factors and to establish a molecular classification for HCC by molecular and genomic approaches combined with immunological analysis. In this symposium, we would like to summarize and discuss recent advances and future challenges in basic and clinical research on HCC, with the aim of further improving the prognosis of HCC patients.

SST5-1 Precision pathology diagnosis of hepatocellular carcinoma Michiie Sakamoto (Dept. Pathol. Keio Univ. Sch. Med.) 肝細胞癌の精密病理診断 坂元 亨宇（慶應大・医・病理）

SST5-2 Liver cancer whole genome analysis Hidewaki Nakagawa (RIKEN IMS) 肝臓がんの全ゲノム解析 中川 英刀（理研・生命医科学）

SST5-3 Hepatic stellate cell autophagy promotes HCC growth via GDF15 Yuta Myojin1, Hayato Hikita1, Takahiro Kodama1, Yuki Makino1, Ryotaro Sakamori1, Tomohide Tatsumi1, Masashi Mizokami3, Hidetoshi Eguchi2, Tetsuo Takehara1 (1Dept. Gastroenterology Hepatology, Osaka Univ. Grad. Sch. of Med., 2Dept. Gastroenterological Surg., Osaka Univ. Grad. Sch. of Med., 3Genome Med. Sci. Project, NCGH) 肝星細胞がオートファジー依存的に分泌するGDF15は肝細胞癌の進展に寄与する 明神 悠太1、疋田 隼人1、小玉 尚宏1、牧野 祐紀1、阪森 亮太郎1、巽 智秀1、溝上 雅史3、江口 英利2、竹原 徹郎1（1大阪大・医・消化器内科、2大阪大・医・消化器外科、3国立国際医療研究セ・ゲノム医科学）

SST5-4 Real-world evidence of multi-systemic therapy for hepatocellular carcinoma Hiroshi Aikata, Masami Yamauchi, Atsushi Ono, Daiki Miki, Masataka Tsuge, Kazuaki Chayama (The Univ. of Hiroshima Gastroenterology & Metabolism) 肝癌薬物療法のreal-world evidence 相方 浩、山内 理海、大野 敦司、三木 大輝、柘植 雅貴、茶山 一彰（広島大・消化器・代謝内科）

SST5-5 Challenge to prevent recurrence after surgical treatment for liver cancer Tsuyoshi Kobayashi, Masahiro Ohira, Masateru Yamamoto, Daisuke Takei, Hirosato Mashima, Michinori Hamaoka, Masakazu Hashimoto, Naoki Tanimine, Shintaro Kuroda, Hiroyuki Tahara, Kentaro Ide, Yuka Tanaka, Hideki Ohdan (Dept. Gastroenterological & Transplant Surg., Hiroshima Univ.) 肝癌外科治療後の再発予防に向けた取り組み 小林 剛、大平 真裕、山本 将輝、竹井 大祐、真島 宏聡、濱岡 道則、橋本 昌和、谷峰 直樹、黒田 慎太郎、田原 裕之、井手 健太郎、田中 友加、大段 秀樹（広島大・消化器移植外科学）

92

8-9

93

Room

9,LSAM

PMLS

AMPM

LSAM

PMLS

DA

Y 1IN

FORM

ATIO

ND

AY 2

DAY 3O

ralM

LIC

IND

EXAuthors

Keywords

ChairpersonsPoster

SSP

Room 7

LS-12 Illumina K.K. イルミナ株式会社

Cancer Genomics –implication of whole genome sequencing- Ken Yamaguchi (Shizuoka Cancer Center)

Chair: Hideki Hanaoka (Regional Segment Marketing, Illumina K.K.)

がんゲノム医療における全ゲノム解析の意義 山口 建（静岡県立静岡がんセンター）

座長：花岡 秀樹（イルミナ株式会社 セグメントマーケティング部）

Live On Demand

Room 8

LS-13 DAIICHI SANKYO COMPANY, LIMITED 第一三共株式会社

Development of treatment strategy for HER2-positive breast cancer Yasuo Miyoshi (Department of Breast and Endocrine Surgery Hyogo, College of

Medicine)

Chair: Masakazu Toi (Kyoto University)

HER2陽性乳癌の治療戦略：新たな展開 三好 康雄（兵庫医科大学 乳腺・内分泌外科）

座長：戸井 雅和（京都大学）

Live Room 4

LS-10 Berkeley Lights Inc. / Nikon Corporation バークレーライツ / 株式会社ニコン

Advanced T Cell Analytics Using Digital Cell Biology at Light Speed Yue Geng (Berkeley Lights Inc.)

Chair: Yasujiro Kiyota (Nikon Corporation )

デジタルセルバイオロジーが開く新しい世界 Yue Geng（Berkeley Lights Inc.）

座長：清田 泰次郎（株式会社ニコン ヘルスケア事業部ステムセル事業推進部）

Live On Demand

Room 5

LS-11 Toray Industries, Inc. 東レ株式会社

RNA Expression and Methylation in Liquid Biopsy Hideshi Ishii (Department of Medical Data Science, Graduate School of Medicine,

Osaka University)

Chair: Takahiro Ochiya (Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University)

RNA発現とメチル化によるリキッドバイオプシーの新展開 石井 秀始（大阪大学大学院 医学系研究科 共同研究講座

疾患データサイエンス学）

座長：落谷 孝広（東京医科大学 医学総合研究所 分子細胞治療研究部門）

Live On Demand

Luncheon Seminars

Room 3

LS-9 MSD K.K. MSD株式会社

Development of cancer immunotherapy based on immunogenome analysis Hiroyoshi Nishikawa (Division of Cancer Immunology, Research Institute/

Exploratory Oncology Research and Clinical Trial Center, National Cancer Center / Department of Immunology, Nagoya University Graduate School of Medicine)

Chair: Takuya Tsunoda (Division of Medical Oncology, Department of Medicine, Showa University School of Medicine)

免疫ゲノム解析に基づくがん免疫併用療法の開発 西川 博嘉（国立がん研究センター 研究所 腫瘍免疫研究分野／先端医療開発

センター 免疫TR分野／名古屋大学大学院 医学系研究科 微生物・免疫学講座 分子細胞免疫学）

座長：角田 卓也（昭和大学 医学部内科学講座 腫瘍内科学部門）

1-2 Core Symposia

Room 1 Oct. 3 (Sat.) 15:00-17:30 E

CS4 Pathological approach pioneers cancer research (JCA-JSP Joint Symposium) 病理が切り拓くがん研究（日本癌学会・日本病理学会 合同シンポジウム）

Chairpersons: Ignacio Wistuba (Translational Mol. Path., Univ. of Texas & MD Anderson Cancer Ctr.) Morii Eiichi (Dept. Path., Osaka Univ. Grad. Sch. of Med.)

座長：Ignacio Wistuba (Translational Mol. Path., Univ. of Texas & MD Anderson Cancer Ctr.) 森井 英一（大阪大・院医・病態病理学・病理診断科）

Pathologists everyday observe tumor cells through microscope. Various interactions take place between tumor and stromal cells. Intra-tumoral interaction also occurs among tumor cells. Live imaging microscope captures vivid appearance of such interactions. Microscopic observation with fixed sample gives us a screen-shot image of such interactions. These interactions determine tumor attitudes and their understanding will lead to the development of novel drugs. This symposium is aimed to talk about “tumors” with members of Japan Society of Pathology (JSP) who everyday observe tumor cells. Live imaging sheds light on novel movement of tumors when they migrate collectively. Observation on tumor-stromal interaction pioneers new anti-cancer therapies. Moreover, images under special type of light give a novel understanding of carcinogensis and progression of tumors. We hope everybody enjoy “tumor worlds” with JSP members.

CS4-1 Heterogenous appearance of tumor cells from the viewpoint of pathologic specimen Eiichi Morii (Dept. Pathol, Osaka Univ. Grad. Sch. Med.) 病理検体からみた腫瘍の多様性 森井 英一（大阪大・医・病態病理学・病理診断科）

CS4-2 Tissue-based Immune-profiling Strategies in Lung Cancer Ignacio Wistuba (Dept. Translational Mol. Path., UT MD Anderson Cancer Ctr.)

CS4-3 Imaging of cancer cell movement Etsuko Kiyokawa (Depi Oncol. Pathol., Kanazawa Med. Univ. Sch. Med.) がん細胞の動態のイメージング 清川 悦子（金沢医大・医・病理学 I）

CS4-4 Stromal biology of cancer and its relevance in developing new anticancer therapeutics Atsushi Enomoto (Dept. Pathol., Nagoya Univ. Grad. Sch. Med.) がんの間質の生物学と新規治療法の開発における重要性 榎本 篤（名古屋大・医・腫瘍病理）

CS4-5 Development of a new mouse model and imaging sensor technology to elucidate the emergence of pancreatic duct carcinoma Ikehara Yuzuru1,2,3, Takashi Yamaguchi1,2, Sanae Ikehara1,3, Mika Hashimoto2, Tomoko Kusano2, Kazuhiko Azuma1 (1Dept. Mol. Tumor Path., Grad. Sch. Med., Chiba Univ., 2Cell, Mol. Tech. Inst., AIST, 3Res. Inst. Adv. Electronics & Photonics, AIST) 膵管がんの発生を解明するための新しいマウスモデルと画像センサー技術の開発 池原 譲1,2,3、山口 高志1,2、池原 早苗1,3、橋本 美香2、草野 知子2、東 和彦1（1千葉大・医学研究院・腫瘍病理、2産総研・細胞分子工学、3産総研・電子光基礎技術）

Symposia on Specific Tumors

Room 2 Oct. 3 (Sat.) 13:45-16:15 J

SST6 Recent progression of pediatric/ adolescent and young adult cancers 小児・AYA腫瘍の最近の進歩

Chairpersons: Eiso Hiyama (Div. Res. & Development, Hiroshima Univ., Natural Ctr. for Basic Res. & Development) Junko Takita (Dept. Pediatrics, Grad. Sch. of Med., Kyoto Univ.)

座長：檜山 英三（広島大・自然科学研究支援開発セ・研究開発部） 滝田 順子（京都大・院医・発達小児科学）

Pediatric cancers are relatively uncommon with approximately 1 in 7,000 children aged at younger than 15 years. However, cancer is the most frequent cause of pediatric mortality in Japan. Overall survival rates for pediatric cancers have improved in the past three decades, while refractory or relapsed cases still have a very poor prognosis, On the other hands, approximately 70,000 new cases of invasive cancer diagnosed annually are among adolescents and young adults (AYA) aged 15 to 39 years. Historically, this age group has not shown the same improved survival as either older or younger cohorts. Therefore, development for new therapeutic strategies for intractable pediatric and AYA cancers is needed. A better understanding of biological features of these cancers is importantly in order to develop more specific and successful treatment strategies. In this Symposium, cutting-age researches in the field of pediatric and AYA cancer will be discussed recent progress across different types of cancer.

SST6-1 Recent progress in rhabdomyosarcoma: differentiation, cell cycle, and cancer metabolism Ken Kikuchi1,2, Hajime Hosoi1 (1Dept. Pediatrics, Kyoto Pref. Univ. of Med., 2Dept. Pediatrics, Uji Takeda Hosp.) 横紋筋肉腫の分化と細胞周期異常およびキャンサーメタボリズム 菊地 顕1,2、細井 創1（1京都府立医大・小児科学教室、2宇治武田病院小児科）

SST6-2 A novel immunotherapeutic approach for osteosarcoma by targeting tumor-associated macrophages Tomohiro Fujiwara1,2,3, Yakoub Mohamed2, Chandler Andrew2, Rajasekhar Vinagolu2, Ouerfelli Ouathek4, Purdue Ed3, Healey John3, Toshifumi Ozaki1 (1Dept. Orthop. Surg., Okayama Univ., Sch. Med., 2Div. Orthop. Surg., Dept. Surg., Memorial Sloan-Kettering Cancer Ctr. r, 3Hosp. for Special Surg., 4Organic Synthesis Core Lab., Memorial Sloan-Kettering Cancer Ctr.) 骨肉腫に対する腫瘍関連マクロファージを標的軸とした新しい免疫療法の開発 藤原 智洋1,2,3、モハメド ヤコブ2、アンドリュー チャンドラー2、ビナゴル ラジャセカー2、オアテック オーフェリ4、エド パードゥー3、ジョン ヒーリー3、尾崎 敏文1（1岡山大・医・整形外科、2スローンケタリング癌セ・整形外科、3ホスピタルフォースペシャルサージェリー、4スローンケタリング癌セ・有機生成）

SST6-3 The roles of a glycosylation-related gene in aggressive osteosarcoma and its potential as a therapeutic target Kentaro Watanabe1, Shota Kato1, Tomoya Isobe1, Eito Ogata2, Keisuke Tasaka2, Hiroo Ueno2,3, Yasuhito Nannya3, Hiroko Tanaka4, Yuichi Shiraishi5, Kenichi Chiba5, Katsutsugu Umeda2, Mitsuteru Hiwatari1,6, Satoru Miyano4, Seishi Ogawa3, Junko Takita2 (1Dept. Ped. The Univ. of Tokyo, 2Dept. Ped. Kyoto Univ., 3Dept. Pathol. & Tumor Biol. Kyoto Univ., 4Lab. DNA information analysis HGC IMS The Univ. of Tokyo, 5Ctr. Cancer Genomics & Advanced Therap. NCC, 6Dept. Cell Therap. & Transplant. Med. The Univ. of Tokyo) 難治性骨肉腫における糖鎖遺伝子の役割と治療標的としての可能性 渡邉 健太郎1、加登 翔太1、磯部 知弥1、緒方 瑛人2、田坂 佳資2、上野 浩生2,3、南谷 泰仁3、田中 洋子4、白石 友一5、千葉 健一5、梅田 雄嗣2、樋渡 光輝1,6、宮野 悟4、小川 誠司3、滝田 順子2（1東京大・医・小児科、2京都大・医・小児科、3京都大・医・腫瘍生物学、4東京大・医科研・HGC DNA情報解析分野、5国立がん研セ・がんゲノム情報・ゲノム解析室、6東京大・医・無菌）

SST6-4 Genomic and molecular biological analyses of pediatric, adolescent and young adult brain tumors Yonehiro Kanemura1,2 (1Dept. Biomed. Res. Innov., Natl. Hosp. Org. Osaka Natl. Hosp., 2Dept. Neurosurg., Natl. Hosp. Org. Osaka Natl. Hosp.) 小児・AYA世代脳腫瘍のゲノム・分子生物学的解析 金村 米博1,2（1大阪医療セ・臨研セ・先進医療研究開発部、2大阪医療セ・脳神経外科）

SST6-5 Omics-analysis of pediatric hematological malignancies Junko Takita (Dept. Pediatr., Grad. Sch. Med., Kyoto Univ.) 小児造血器腫瘍におけるオミックス解析 滝田 順子（京都大・医・小児科）

94

SST6-6 NCC Oncopanel Ped: A novel cancer gene panel test for pediatric solid tumors Fumito Yamazaki1,2, Takashi Kubo1,3, Kuniko Sunami3, Takafumi Koyama4, Ayumu Arakawa5, Sachiyo Mitani1, Miki Ohira6, Motohiro Kato7, Atsuko Nakazawa8, Takashi Kohno9, Noboru Yamamoto4, Takehiko Kamijo6, Tomoro Hishiki10, Chitose Ogawa5, Hitoshi Ichikawa1 (1Dept. Clin. Genomics, Natl. Cancer Ctr. Res. Inst., 2Dept. Ped., Keio Univ., 3Dept. Lab. Med., Natl. Cancer Ctr. Hosp., 4Dept. Exp. Therap., Natl. Cancer Ctr. Hosp., 5Dept. Ped., Natl. Cancer Ctr. Hosp., 6Res. Inst. for Clin. Oncol., Saitama Cancer Ctr., 7Child. Cancer Ctr., Natl. Ctr. for Child Health & Dev., 8Dept. Clin. Res., Saitama Child. Med. Ctr., 9Div. Genome Biol., Natl. Cancer Ctr. Res. Inst., 10Dept. Ped. Surg., Chiba Univ.) 小児固形腫瘍のための遺伝子パネル検査：NCC Oncopanel Ped 山崎 文登1,2、久保 崇1,3、角南 久仁子3、小山 隆文4、荒川 歩5、三谷 幸代1、大平 美紀6、加藤 元博7、中澤 温子8、河野 隆志9、山本 昇4、上條 岳彦6、菱木 知郎10、小川 千登世5、市川 仁1（1国立がん研究セ・研・臨床ゲノム、2慶應大・小児科、3国立がん研セ・中央病院・臨床検査科、4国立がん研セ・中央病院・先端医療科、5国立がん研セ・中央病院・小児腫瘍科、6埼玉がんセ・臨床腫瘍研、7国立成育研セ・小児がんセ、8埼玉小児セ・臨床研究部、9国立がん研セ・研・ゲノム生物、10千葉大・小児外科）

SST6-7 Tumor-tropic liposome-mediated therapeutic delivery of mRNA for pediatric / adolescent and young adult cancers Shoji Saito1, Eiichi Akahoshi2, Mitsuko Ishihara-Sugano2, Shigeki Yagyu1, Yozo Nakazawa1 (1Dept. Pediatrics, Shinshu Univ. Sch. of Med., 2Corporate Res. & Development Ctr., Toshiba Corporation) 小児AYAがんに対する腫瘍指向性リポソームを用いた新規mRNA医薬の開発 齋藤 章治1、赤星 英一2、菅野 美津子2、柳生 茂希1、中沢 洋三1（1信州大・医・小児医学教室、2東芝 開発研究セ）

Symposia

Room 3 Oct. 3 (Sat.) 13:45-16:15 E

S18 Metabolism in Cancer がんと代謝 (免疫代謝を含む）

Chairpersons: Keiichi Nakayama (Dept. Mol. & Cell. Biol., Med. Inst. of Bioregulation, Kyushu Univ.) Naoko Ohtani (Osaka City Univ., Grad. Sch. of Med., Dept. Pathophysiology)

座長：中山 敬一（九州大・生医研・分子医科学分野） 大谷 直子（大阪市大・院医・病態生理学）

The metabolic alterations in cancer cells has been recently recognized as one of the hallmarks of cancer, and their metabolic features are shown to be associated with the transformation and the progression of cancer cells. This symposium entitled “Metabolism in Cancer“ will show you the recent leading-edge topics on metabolism/metabolites in cancer by six presentations including four invited and two short talks selected from open participants. The topics include the role of glycolytic enzyme, PKM1 in small cell lung cancer, the importance of branched chain amino acid transferase (BCAT1) in chronic myeloid leukemia, the unveiled role of glutamine metabolism in cancer by proteomics analyses, and the effect of gut microbial metabolites on liver cancer as well as the glutamine-regulated tumor plasticity and the metabolic vulnerability in prostate cancer. We welcome lively discussions.

S18-1 A dietary intervention enhances new metabolism-targeting therapy of deadly lung cancer in mouse preclinical models. Nobuhiro Tanuma (Div. Cancer Chemother., Miyagi Cancer Ctr. Res. Inst.) 食事介入を活用した、難治肺がんに対する新たな代謝ターゲット治療 田沼 延公（宮城がんセ研・がん薬物療法）

S18-2 Gut microbial metabolite and obesity-associated liver cancer Naoko Ohtani, Tomonori Kamiya, Fumitaka Kamachi, Ryota Yamagishi (Dept. Pathophysiol., Osaka City Univ. Grad. Sch. Med.) 腸内細菌代謝物と肥満関連肝がん 大谷 直子、神谷 知憲、蒲池 史卓、山岸 良多（大阪市大・院医・病態生理）

S18-3 Regulation of amino acid metabolism in myeloid leukemia Ayuna Hattori1, Issay Kitabayashi1, Takahiro Ito2 (1Div. Hematological Malignancy, NCC, 2Kyoto Univ. Inst. for Frontier Life & Med. Sci.) 白血病におけるアミノ酸代謝制御 服部 鮎奈1、北林 一生1、伊藤 貴浩2（1国立がん研セ・造血器腫瘍研究分野、2京都大・ウイルス再生研）

S18-4 Metabolic dynamics within tumor microenvironments towards cancer plasticity Tsuyoshi Osawa1, Teppei Shimamura2, Tomohiro Arai1, Arisa Hoashi1, Miyuki Nishida1, Maki Sugaya1, Rika Tsuchida1, Hiroyuki Aburatani4, Tomoyoshi Soga3 (1Nutriomics & Onc., RCAST, Univ. of Tokyo, 2System Biol. Nagoya Univ., 3Advanced Sci. Keio Univ., 4Genome Sci. RCAST, Univ. of Tokyo) がん微小環境における代謝ダイナミクスとがん細胞の可塑性 大澤 毅1、島村 徹平2、新井 智大1、帆足 安理佐1、西田 美由紀1、菅谷 麻希1、土田 里香1、油谷 浩幸4、曽我 朋義3（1東京大・先端研・ニュートリオミクス・腫瘍、2名古屋大・医・システム生物、3慶應大・先端生命科学研、4東京大・先端研・ゲノムサイエンス）

S18-5 Pharmacologically targetable metabolic vulnerability in prostate cancer carrying RB1-SUCLA2 deletion Susumu Kohno1, Tomoyoshi Soga2, Chiaki Takahashi1 (1Div. Oncol. Mol. Biol., Cancer Res. Inst., Kanazawa Univ., 2Inst. for Adv. Biosci., Keio Univ.) RB1-SUCLA2欠損による代謝脆弱性を標的とした前立腺がん治療法の探索 河野 晋1、曽我 朋義2、高橋 智聡1（1金沢大・がん研・腫瘍分子生物学、2慶應大・先端生命科学研）

S18-6 A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer Keiichi I. Nakayama (Dept. Mol. Cell. Biol., Med. Inst. Bioreg., Kyushu Univ.) グルタミンからの窒素代謝の変化はがんの悪性進化に必要である：”第二のワールブルグ効果”の発見 中山 敬一（九州大・生医研・分子医科学）

95

Room

1-3 AM

PMLS

AMPM

LSAM

PMLS

DA

Y 1IN

FORM

ATIO

ND

AY 2

DAY 3O

ralM

LIC

IND

EXAuthors

Keywords

ChairpersonsPoster

SSP

4-5 Symposia

Room 4 Oct. 3 (Sat.) 13:45-16:15 E

S19 RNA biology in cancer research

Chairpersons: Takashi Takahashi (Aichi Cancer Ctr.) Hidetoshi Tahara (Grad. Sch. of Biomed. & Health Sci., Hiroshima Univ.)

座長：高橋 隆（愛知県がんセ） 田原 栄俊（広島大・院医・細胞分子生物学）

A wide variety of RNA molecules such as messenger RNA, t-RNA, rRNA, miRNA and lncRNA are known to dysregulated in cancer, which may cause cancer progression and metastasis. In addition, RNA modification patterns and RNA splicing are widely linked to development of cancer, and the dys-regulation of RNA modification pathways and RNA splicing also emerged as a contributor to cancer. In this symposium, researcher who are specialists of these fields of RNA in cancer research. We will discuss the latest topics of RNA in cancer.

S19-1 Pre-mRNA processing factor 19 (PRPF19) as a key regulator in aging and cancer Hidetoshi Tahara (Dept. Cell. Mol. Biol, Grad. Sch. Biomed. Health Sci., Hiroshima Univ.) スプライシング因子PRPF19 は、細胞老化、癌においてカギを握る因子である。 田原 栄俊（広島大・院・細胞分子生物）

S19-2 A Thread in the Tapestry of Science: Aging and Cancer Curtis C Harris (LHC, NIH, NCI, Bethesda, MD, USA)

S19-3 A novel long non-coding RNA, TILR, suppresses the apoptosis by inhibiting p53 expression Taisuke Kajino1, Takashi Takahashi2 (1Div. Mol. Diag., Aichi Cancer Ctr. Res. Inst., 2Aichi Cancer Ctr.) p53 を抑制する新規 lncRNA、TILR の同定とその機能解明 梶野 泰祐1、高橋 隆2（1愛知セ・研・分子診断 TR、2愛知県がんセ）

S19-4 miRNA Methylation Hideshi Ishii (Med. Data Sci. Osaka Univ. Sch. Med.) miRNAメチル化 石井 秀始（大阪大・医・疾患データ）

International Sessions

Room 5 Oct. 3 (Sat.) 13:45-16:15 E

IS11 Epigenetic therapeutic targets in cancer microenvironment がん微小環境を標的としたエピジェネティクス治療

Chairpersons: Yutaka Kondo (Div. Cancer Biol., Nagoya Univ. Grad. Sch. of Med.) Alfred Sze-Lok Cheng (Sch. of Biomed. Sci., The Chinese Univ. of Hong Kong)

座長：近藤 豊（名古屋大・院医・腫瘍生物学） Alfred Sze-Lok Cheng (Sch. of Biomed. Sci., The Chinese Univ. of Hong Kong)

Altered epigenetic regulation is not only limited in cancer cells, but also associated with reprogramming of microenvironmental stromal-inflammatory components, angiogenesis, and immune escape. Recent studies have demonstrated that targeting epigenetic regulatory mechanism in such cancer-associated cells may provide a new paradigm for translational research. We invite you to join Symposium Cochairs Yutaka Kondo and Alfred Cheng as we discuss the growing interest in virus associated reprogramming, epigenetic regulation of tumor immune reaction, EMT and metabolism, as well as non-coding RNA based DNA maintenance system. Our deeper mechanistic understanding may lead to development of new therapies and efficient combination with epigenetic drugs for cancer treatment. The goal of this Symposium is to offer novel insight into the expanding repertoire of epigenetic translational research.

IS11-1 Epigenetic and transcriptional control of epithelial-mesenchymal plasticity Muh-Hwa Yang1,2 (1Inst. of Clin. Med., Natl. Yang-Ming Univ., Taipei, Taiwan, 2Div. Med. Oncology, Taipei Veterans General Hosp., Taipei, Taiwan)

IS11-2 Histone Demethylase KDM4C promotes prostate cancer metastasis via modulation of c-Myc and metabolism rewiring Chih-Pin Chuu1, Ching-Yu Lin1, Bi-Juan Wang1, Chiou-Hwa Yuh2 (1ICSM, NHRI, 2IMGM, NHRI)

IS11-3 Chromatin Structural Aberrations due to oncovirus infection activate neighboring oncogenes through enhancer activation Atsushi Okabe1, Kie Kyon Huang2, Keisuke Matsusaka1, Masaki Fukuyo1, Bahityar Rahmutulla1, Patrick Tan2, Atsushi Kaneda1 (1Dept. Mol. Oncol., Grad. Sch. of Med., Chiba Univ., 2Cancer Sci. Inst. of Singapore) 癌ウイルス感染がもたらすクロマチン構造異常による癌遺伝子の活性化 岡部 篤史1、Kie Kyon Huang2、松坂 恵介1、福世 真樹1、Bahityar Rahmutulla1、Patrick Tan2、金田 篤志1（1千葉大・院医・分子腫瘍学、2Cancer Sci. Inst. of Singapore）

IS11-4 HTLV-1 bZIP factor RNA and Protein induce TP73 to enhance the survival of ATL cells Kosuke Toyoda1, Jun-ichirou Yasunaga1, Azusa Tanaka2, Masao Matsuoka1 (1Hematol., Rheumatol., & Infectious Diseases, Kumamoto Univ., Kumamoto, Japan, 2Human Genetics, Tokyo Univ., Tokyo, Japan) HBZ RNAとタンパク質はTP73を発現誘導することによりATL 細胞の生存を促進する 豊田 康祐1、安永 純一朗1、田中 梓2、松岡 雅雄1（1熊本大・血液・膠原病・感染症内科、2東京大・健康総合化学科・人類遺伝学）

IS11-5 Long Non-coding RNA TUG1 governs replication stress in cancer cells Kenta Iijima1, Miho Suzuki1, Keiko Shinjo1, Junya Kobayashi2, Yutaka Kondo1 (1Div. Cancer Biol., Nagoya Univ. Grad. Sch. of Med., 2Narita Internatl. Univ. of Health & Welfare) 長鎖非翻訳RNA TUG1はがん細胞の複製ストレスを制御する 飯島 健太1、鈴木 美穂1、新城 恵子1、小林 純也2、近藤 豊1（1名古屋大・院医・腫瘍生物学、2国際医療福祉大・成田保健医療学部）

IS11-6 Delineating the epigenetic vulnerabilities of tumor immune evasion for combination immunotherapy Alfred Cheng (Sch. of Biomed. Sci., The Chinese Univ. of Hong Kong)

96

3-4

International Sessions

Room 7 Oct. 3 (Sat.) 13:45-16:15 E

IS12 Infection and cancer: risk estimation and therapeutic targets 感染とがん：リスク評価と治療戦略

Chairpersons: Atsushi Kaneda (Dept. Mol. Oncology, Grad. Sch. of Med., Chiba Univ.) Khay Guan Yeoh (Natl. Univ. of Singapore)

座長：金田 篤志（千葉大・院医・分子腫瘍学） Khay Guan Yeoh (Natl. Univ. of Singapore)

Cancer is caused by genomic and epigenomic aberrations that are accumulated though exposure to tumorigenic environments. One of the major tumorigenic environment is infection of pathogens, such as viruses, bacteria, and parasites. Recent comprehensive analyses have stratified cancer into distinct molecular subtypes exhibiting unique genomic and epigenomic profiles, which can be associated with its background environments including pathogen infection and tumorigenic pathway. In this Session, speakers invited from Asia and Japan will talk on variable pathogens including Helicobactor pylori, Epstein-Barr virus (EBV), human papillomavirus (HPV), hepatitis B virus (HBV), and liver fluke, and tumor types including gastric cancer, head and neck cancer, liver cancer, and biliary tract cancer. We will discuss how these pathogens can modify tumor risk through induction of unique genomic and epigenomic aberrations and alteration of critical signaling pathways, and how these aberrations can be clinically utilized, which will help us uncover genesis of these tumors and establish novel therapeutic strategies.

IS12-1 Risk of Gastric Cancer following H pylori eradication and precision strategies for surveillance Khay Guan Yeoh1,2,3 (1Dept. Med., Natl. Univ. of Singapore, 2Dept. Gastroenterology & Hepatology, Natl. Univ. Hosp., Singapore, 3Singapore Gastric Cancer Consortium)

IS12-2 Impact of virus integration on development of hepatocellular carcinoma Kenji Tatsuno1, Yutaka Midorikawa1,3, Natsuko Hama4, Genta Nagae1, Hiroki Ueda2, Tadatoshi Takayama3, Tatsuhiro Shibata4, Hiroyuki Aburatani1 (1Genome Sci. Lab., RCAST, Univ. of Tokyo, 2Biological Data Sci., RCAST, Univ. of Tokyo, 3Dpet. Digestive Surg., Nihon Univ. Sch. Med., 4Div. Cancer Genomics, NCCRI) ウイルスインテグレーションと肝がん 辰野 健二1、緑川 泰1,3、濱 奈津子4、永江 玄太1、上田 宏生2、高山 忠利3、柴田 龍弘4、油谷 浩幸1（1東京大・先端研・ゲノムサイエンス、2東京大・先端研・生命データサイエンス、3日本大・医・消化器外科、4国立がん研セ・研・がんゲノミクス）

IS12-3 Screening for Nasopharyngeal Cancer in asymptomatic men by Liquid Biopsy K.C. Allen Chan (Dept. Chem. Pathol., CUHK)

IS12-4 Complete viral genome sequencing of Japanese tonsil-derived EBV strains and their global phylogenetic positions Teru Kanda (Div. Microbiol., Faculty of Med., Tohoku Med. & Pharm. Univ.) 日本人扁桃由来EBウイルス株の全ウイルスゲノム塩基配列決定、および世界における系統学的位置 神田 輝（東北医薬大・医・微生物）

IS12-5 Liver Fluke-Associated Biliary Tract Cancer: Molecular Biology and Genomic Landscape Apinya Jusakul1 (1CARI, KKU, 2CMDL, KKU)

IS12-6 Epigenetic stratification of HPV-associated oropharyngeal squamous cell carcinoma and new therapeutic strategies Takuya Nakagawa1,2,3, Keisuke Matsusaka1,4, Tomoya Kurokawa1,2, Toyoyuki Hanazawa2, Joseph A. Califano3, Atsushi Kaneda1 (1Dept. Mol. Oncol, Grad. Sch. Med., The Univ. of Chiba, 2Dept. Oto, Grad. Sch. Med., The Univ. of Chiba, 3MooRes. Cancer Ctr., The Univ. of California, San Diego, 4Dept. Path., Chiba Univ. Hosp.) HPV関連頭頸部腫瘍である中咽頭癌の網羅的解析による層別化と新規治療戦略の探索 中川 拓也1,2,3、松坂 恵介1,4、黒川 友哉1,2、花澤 豊行2、Joseph A. Califano3、金田 篤志1（1千葉大・院医・分子腫瘍学、2千葉大・院医・耳鼻咽喉科、3カリフォルニア大・サンディエゴ校、4千葉大・医附属病院・病理診断科）

Symposia

Room 8 Oct. 3 (Sat.) 13:45-16:15 E

S20 4D Nucleome in cancer がんの4Dヌクレオーム研究

Chairpersons: Satoshi Tashiro (Dept. Cell. Biol., Res. Institite for Radiation Biol. & Med., Hiroshima Univ.) Noriko Saitoh (Div. Cancer Biol., The Cancer Inst. of JFCR)

座長：田代 聡（広島大・原医研・細胞修復制御） 斉藤 典子（（公財）がん研・研・がん生物部）

Recent advances in microscopic imaging and high-throughput sequencing technologies have greatly improved our understanding of the biological significance of nuclear architectures in genome function. For instance, super-resolution microscopy has revealed the dynamics and mechanisms of nuclear structures associated with transcription, replication and DNA repair. Genome-wide chromatin interaction analyses using deep sequencing have introduced novel concepts of topologically associating domains, TADs, and A/B-compartments. They are mega base-sized chromatin domains, and their abnormal formation is associated with tumorigenesis and cancer progression. The term “4D Nucleome” refers to dynamic spatiotemporal regulations of 3D genome architecture and function in the cell nucleus. In this session, we assemble the latest studies on cancer 4D Nucleome, aiming to elucidate cancer biology. Moreover, we will discuss on the state-of-the-art technologies for the 4D Nucleome. These efforts will contribute to our understanding of cancer etiology, and pave the way for novel cancer diagnosis and therapies.

S20-1 Mechanism of chromosome translocations in leukemia Satoshi Tashiro, Jiying Sun (Dept. Cell. Biol., RIRBM, Hiroshima Univ.) 白血病の染色体転座形成機構 田代 聡、孫 継英（広島大・原医研・細胞修復制御）

S20-2 Spatial-temporal regulation of Aurora B kinase activity through liquid-liquid phase separation Ryu-Suke Nozawa, Toru Hirota (Div. Exp. Pathol. Cancer Inst. JFCR) 液-液相分離を介したAurora B キナーゼの活性化の時空間的な制御機構 野澤 竜介、広田 亨（（公財）がん研・研・実験病理部）

S20-3 Chromatin modification dynamics and gene regulation in living cells Hiroshi Kimura (Cell Biol. Ctr., Inst. Innov. Res., Tokyo Tech.) 生細胞における遺伝子制御とクロマチン修飾ダイナミクス 木村 宏（東工大・科技創研・細胞制御）

S20-4 Local nucleosome motion in living human cells revealed by single nucleosome imaging Kazuhiro Maeshima (NIG) 1 分子ヌクレソームイメージングで明らかにするヒト生細胞でのヌクレオソーム動態 前島 一博（遺伝研・遺伝メカニズム）

S20-5 Development of single-molecule and super-resolution imaging toward application in cancer cells. Yasushi Okada1,2,3 (1Dept. Phys, Grad. Sch. Sci., Univ. Tokyo, 2Dept. Cell Biol., Grad. Sch. Med., Univ. Tokyo, 3BDR, RIKEN) がん細胞内での定量的計測を目指したバイオイメージング技術の開発 岡田 康志1,2,3（1東京大・理・物理、2東京大・医・細胞生物、3理研BDR）

S20-6 Non-coding RNAs in the 3D genome architecture in recurrent breast cancer Noriko Saitoh, Yuichi Ichikawa, Megumi Fukuoka, Hiroaki Tachiwana, Tatsuro Yamamoto (The Cancer Inst. of JFCR) 再発乳がんの3次元ゲノム構造を司るノンコーディングRNA 斉藤 典子、市川 雄一、福岡 恵、立和名 博昭、山本 達郎（（公財）がん研・研）

97

Room

4-8 6-7

AMPM

LSAM

PMLS

AMPM

LSD

AY 1

INFO

RMA

TION

DA

Y 2DAY 3

Oral

ML

ICIN

DEX

AuthorsKeyw

ordsChairpersons

PosterSSP

Symposia

Room 9 Oct. 3 (Sat.) 13:45-16:15 E

S21 Hereditary Cancer Research -Recent Updates and Future Directions 遺伝性腫瘍　̶最新情報と今後の方向性

Chairpersons: Yoshio Miki (Dept. Mol. Genetics, Med. Res. Inst., Tokyo Med. & Dent. Univ.) Haruhiko Sugimura (Dept. Tumor Path., Hamamatsu Univ. Sch. of Med.)

座長：三木 義男（東京医歯大・難治研・分子遺伝分野） 椙村 春彦（浜松医大・医・腫瘍病理学）

Genome medicine has a major impact in guiding diagnoses and treatment, especially in the fields of oncology. In cancer genome medicine, the area of hereditary tumor has been a typical example showing us the development from basic research to clinical practice was so important. Significant advances of technology in next-generation sequencing have led to major changes in the research and clinical practice of hereditary tumors. Moreover, "clinical sequencing" in cancer genome medicine has been implemented, and it also became important to consider how to manage a secondary finding in identified in practice of hereditary tumor medicine. In this session, we will have 6 speakers presenting on various topics such as genome study of hereditary tumors based on NGS technology, hereditary breast and ovarian cancers, hereditary gastrointestinal tumors, search for therapeutic target of NF-associated tumors, multi-gene panel testing for hereditary tumors, and appropriate disclosure of genomic information in genome medicine. We hope that researchers and experts at the forefront of hereditary tumors will exchange views on current issues related to hereditary tumors and that information will be useful for research and therapy in the near future.

S21-1 Large-sale genomic analysis in hereditary cancer Yukihide Momozawa (RIKEN Ctr. for Integrative Med. Sci.) 遺伝性腫瘍の大規模ゲノム解析 桃沢 幸秀（理研・生命科学研究セ）

S21-2 Prevalence of Causal Genes in Japanese Patients with BRCA1/2-Wildtype Hereditary Breast and Ovarian Cancer Syndrome Seiichi Mori (CPM ctr., Jpn. Fdn. for Cancer Res.) 日本人BRCA1/2 変異陰性遺伝性乳がん卵巣がん症候群における既知原因遺伝子の頻度 森 誠一（（公財）がん研・CPMセ）

S21-3 Frontiers in the research for hereditary intestinal tumors Yoichi Furukawa1, Kiyoshi Yamaguchi1, Rika Kasajima2, Eigo Shimizu2, Kiyoko Takane1, Rui Yamaguchi2,3, Seiya Imoto2, Satoru Miyano2,4, Tsuneo Ikenoue1 (1Div. Clin. Genome Res., Inst. Med. Sci., Univ. Tokyo, 2Lab. DNA Information Analysis, Inst. Med. Sci., Univ. Tokyo, 3Div. Cancer Sys. Bio., Aichi Cancer Ctr. Res. Inst., 4M&D Data Sci. Ctr., TMDU) 消化管遺伝性腫瘍の最前線 古川 洋一1、山口 貴世志1、笠島 理加2、清水 英悟2、高根 希世子1、山口 類2,3、井元 清哉2、宮野 悟2,4、池上 恒雄1（1東京大・医科研・臨床ゲノム、2東京大・医科研・DNA情報解析、3愛知県がんセ・システム解析、4東京医歯大・M&Dデータ科学センター）

S21-4 Identification of novel target signalings and function of NF1-associated tumor progression Norie Araki, Daiki Kobayashi (Grad. Sch. of Med. Sci., Kumamoto Univ.) NF1腫瘍の新規治療ターゲットシグナルの同定と機能解析 荒木 令江、小林 大樹（熊本大・院生命科学研究部腫瘍医学講座）

S21-5 Practical impacts of multi-gene cancer profiling on cancer precision medicine and hereditary tumor Hideki Yamamoto1,2, Toshio Kubo3, Shuta Tomida4, Daisuke Ennishi4, Shinichi Toyooka4,5, Akira Hirasawa1,2,4 (1Dept. Clin. Genomic Med., Grad. Sch., Okayama Univ., 2Dept. Clin. Genomic Med., Okayama Univ. Hosp., 3Ctr. for Clin. Oncol., Okayama Univ. Hosp., 4Ctr. for Comprehensive Genomic Med., Okayama Univ. Hosp., 5Dept. General Thoracic, Breast & Endocrine Surg., Grad. Sch., Okayama Univ.) がん遺伝子パネル検査によるがん個別化医療と遺伝性腫瘍への実効果 山本 英喜1,2、久保 寿夫3、冨田 秀太4、遠西 大輔4、豊岡 伸一4,5、平沢 晃1,2,4（1岡山大・院医歯薬・臨床遺伝子医療学、2岡山大・病院・臨床遺伝子診療科、3岡山大・病院・腫瘍セ、4岡山大・病院・ゲノム医療総合推進セ、5岡山大・院医歯薬・呼吸器乳腺内分泌外科）

S21-6 Proposal concerning the information transmission process in genomic medicine, focusing on tumor profiling analysis. Shinji Kosugi (Dept. Med. Ethics/Med. Genetics, Kyoto Univ., Sch. Public Health) がんゲノム医療における情報伝達プロセス 小杉 眞司（京都大・医療倫理学・遺伝医療学）

98

8-9